Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 913 of 5804
-
New surgical twist may save sight in babies with rare glaucoma
Disease control CompletedPrimary congenital glaucoma (PCG) is a vision-threatening disorder of childhood characterized by elevated intraocular pressure (IOP) resulting from developmental abnormalities of the anterior chamber angle. Early surgical intervention is the standard treatment to preserve visual …
Phase: NA • Sponsor: Benha University • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Second chance: new combo aims to clear hepatitis c after relapse
Disease control OngoingThis multicenter study evaluates the effectiveness and safety of a 12-week regimen of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C who relapsed after prior direct-acting antiviral therapy. The study assesses the rate of sustained virologic response aft…
Sponsor: Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental antibody aims to quiet spinal inflammation without X-Ray damage
Disease control TerminatedThe purpose of this study is to evaluate preliminary efficacy, safety pharmacokinetic (PK) characteristics, pharmacodynamics (PD) haracteristics and immunogenicity of JS005 at different doses in Chinese patients with active non-radiographic axial spondyloarthritis(nr-axSpA). Trea…
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug shows promise for painful skin condition
Disease control CompletedThis is a Phase 2a study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ATI-450 vs placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
Phase: PHASE2 • Sponsor: Aclaris Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Could a daily pill lower breast cancer risk by reducing breast density?
Disease control CompletedThis is a randomized, double-blinded, placebo-controlled dose-response efficacy study of oral (Z)-endoxifen in premenopausal women with measurable breast density. There will be 5 in-clinic visits (Screening, Day 1, Months 1, 3 and 6) and 3 self-report visits (Months 2, 4 and 5). …
Phase: PHASE2 • Sponsor: Atossa Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Oxygen test during pregnancy may predict brain development in Heart-Defect babies
Knowledge-focused CompletedDetermine 1) the impact of abnormal fetal cerebrovascular physiology with neurodevelopmental delay (ND) outcomes and 2) how this relationship is modified by patient and environmental factors such as chronic congenital heart disease (CCHD) lesion, maternal-fetal environment, and s…
Phase: PHASE2, PHASE3 • Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Brain electrode recordings during awake surgery could sharpen tumor removal
Knowledge-focused TerminatedThis study proposes to analyze data from intraoperative ECoG recordings acquired during wakefulness interventions in order to identify the connection networks involved in cognitive functions. This study also proposes to correlate the ECoG data with the imaging data and to analyze…
Phase: NA • Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
New Shoe-Like device aims to heal diabetic foot sores faster
Disease control CompletedThe purpose of this clinical investigation is to assess the safety and performance of Compedica's OptiPulse™ and to collect subject outcome data on the treatment of diabetic foot ulcers (DFU's) versus the standard of care (SOC). OptiPulse™ is designed to enhance blood circulation…
Phase: NA • Sponsor: Compedica Inc • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Smaller tube, same stone removal: new kidney stone surgery tested
Disease control CompletedPercutaneous nephrolithotomy (PCNL) is recommended as the first-line treatment choice for kidney stones larger than 2cm in international guidelines . However, tract-related complications affecting renal parenchymal and blood vessels have always been a concern . The mini-PCNL tech…
Phase: NA • Sponsor: The First Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New device aims to curb opioid withdrawal without drugs
Symptom relief OngoingThis prospective, randomized, double-blind, parallel-group, sham-controlled, superiority study will evaluate the effectiveness of the NET Device in treating persons with Opioid Use Disorder (OUD) without use of Medications for OUD (MOUD) for persons who have expressed a desire to…
Phase: NA • Sponsor: Wayne State University • Aim: Symptom relief
Last updated Jun 26, 2026 18:14 UTC
-
New PET scan agent could spot childhood cancer more clearly
Diagnosis OngoingThis is a Phase 3 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for confirming or excluding the presence of neuroblastoma
Phase: PHASE3 • Sponsor: Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
Alzheimer's drug simufilam trial halted Mid-Study
Disease control TerminatedA 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 weeks. Approximately 1083 participants will be randomized (1:1:1) to receive either placebo, 50 mg tablets of simufilam, or 100 mg ta…
Phase: PHASE3 • Sponsor: Cassava Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Heart procedure put to the test: real relief or placebo?
Symptom relief OngoingBeing the most common arrhythmia, atrial fibrillation (AF) is a high burden of public health with an increasing prevalence in our aging population. Interventional treatment of atrial fibrillation by catheter ablation is one of the treatment pillars in the complex field of "better…
Phase: NA • Sponsor: University of Leipzig • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
New Long-Acting pill could smooth Parkinson's symptoms
Disease control CompletedIt is a phase II randomized, parallel, double-blind, placebo-controlled, multi-center clinical trial of the efficacy and safety of WD-1603 Carbidopa-Levodopa Extended-Release Tablets in patients with Parkinson's disease. The objective of the study is to access the safety and effi…
Phase: PHASE2 • Sponsor: Shanghai WD Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New 3D imaging technique could replace pressure wire in heart artery procedures
Disease control CompletedThe FAST III is a randomized controlled, open-label, multicenter, international, non-inferiority, strategy trial. A total of 2228 participants will be randomized in a 1:1 fashion to either vFFR- or FFR guided revascularization. Patients will be consented prior to the procedure an…
Phase: NA • Sponsor: ECRI bv • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Sound waves may make heart stenting safer for High-Risk patients
Disease control CompletedThe IVUS CHIP trial is a post-marketing strategy study in which patients with complex coronary lesions, undergoing percutaneous coronary intervention (PCI), are treated either with intravascular ultrasound (IVUS) guided PCI or angiographic guided PCI . The IVUS-guided PCI approa…
Phase: NA • Sponsor: ECRI bv • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Zapping the brain to fight seizure blackouts: a new hope for epilepsy
Symptom relief CompletedThe goal is to provide a novel therapeutic option for temporal lobe epilepsy patients when focal impaired awareness seizures cannot be stopped by medications, surgical or laser ablation, or by neurostimulation. The goal is restore consciousness when seizures cannot be stopped. If…
Phase: NA • Sponsor: Yale University • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
New hope for rare cancer: trabectedin vs gemcitabine in leiomyosarcoma trial
Disease control Recruiting nowStudy is aimed at evaluating the activity of Trabectedin (arm A) in advanced leiomyosarcomas, having Gemcitabine (arm B) as the comparator. In addition to the randomized cohort, the study has also an observational prospective cohort which include patients who will refuse the ran…
Phase: PHASE2 • Sponsor: Italian Sarcoma Group • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo aims to free hepatitis b patients from daily pills
Disease control CompletedThis is a randomized, open label, multicenter Phase 2 study investigating the safety and antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of Peg-IFNα-2a in subjects with CHB.
Phase: PHASE2 • Sponsor: Arbutus Biopharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Which progesterone works best to stop preterm birth? 820 women studied
Prevention CompletedPreterm labour is a major cause of neonatal morbidity and mortality worldwide. Progesterone supplementation is known to help reduce the risk of preterm birth in high-risk women. This randomized controlled trial compared the effectiveness of intramuscular progesterone and rectal p…
Phase: NA • Sponsor: Hina Mukhtar • Aim: Prevention
Last updated Jun 27, 2026 08:07 UTC